H.C. Wainwright raised the firm’s price target on Argenx (ARGX) to $940 from $915 and keeps a Buy rating on the shares. The firm cites the company’s momentum and the addition of new pipelines for the target boost.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx price target raised to $944 from $925 at Citizens
- Argenx price target lowered to $1,227 from $1,248 at Stifel
- Vyvgart’s Strengthening MG Franchise and Pipeline Catalysts Support Buy Rating on Argenx
- Argenx Posts First Operating Profit on Surging VYVGART Sales and Expanding Autoimmune Pipeline
- Argenx Reports Positive Phase 3 VYVGART Data in Ocular Myasthenia Gravis